Center of Innovation for Brain Tumor Therapeutics

脑肿瘤治疗创新中心

基本信息

批准号：
10305361
负责人：
Ranjit Bindra
金额：
$ 124.38万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10305361
关键词：
Address Adjuvant Aftercare Animal Model Biological Assay Biopsy Biotechnology Brain Brain Neoplasms Clinic Clinical Collaborations Communities Cytotoxic Chemotherapy DNA Damage Data Development Drug Exposure Drug Targeting Evaluation Excision Fostering Funding Genomic Instability Glioblastoma Glioma Goals Gold Grant Heterogeneity Human Impairment Infiltration Investigation Laboratories Leadership Manuscripts Medical Oncology Modeling Molecular New Drug Approvals Normal tissue morphology Operative Surgical Procedures Patients Pharmaceutical Preparations Pharmacologic Substance Pharmacology Physicians Population Heterogeneity Preclinical Testing Publishing Radiation Radiation Oncology Radiation therapy Research Risk Sampling Scientist Structure Systems Biology Testing Therapeutic Therapy Evaluation Translating Translational Research Treatment Failure Tumor Biology Tumor Tissue United States National Institutes of Health Work animal tissue cancer therapy cerebral microvasculature chemotherapy clinical development clinical translation cohort combinatorial drug distribution drug efficacy effective therapy genotoxicity human tissue inhibitor/antagonist innovation member multidisciplinary neoplastic cell neuro-oncology neurosurgery novel therapeutic intervention novel therapeutics outreach patient derived xenograft model pharmacokinetics and pharmacodynamics pre-clinical research clinical testing response small molecule temozolomide therapeutically effective therapy resistant tool translational study tumor tumor heterogeneity tumorigenesis

项目摘要

PROJECT DESCRIPTION/ABSTRACT – OVERALL The development of effective therapies for glioblastoma (GBM) has been incredibly vexing with no new drug approvals in over a decade. Therapeutic resistance in any one patient with GBM can be related to multiple factors including extensive tumor cell infiltration into adjacent brain, molecular heterogeneity of tumor cell populations, and heterogeneity of drug distribution. In order to understand and overcome these challenges, we have built a highly productive, multi-disciplinary scientific team over the past decade with expertise spanning systems biology, pharmacology, tumor biology, and animal models of GBM. In the proposed U19 Center application, we will integrate this established cross-disciplinary translational science team with physician scientists in radiation and medical oncology, neurosurgery and neuroradiology with a collective focus of translating novel therapeutic strategies into highly effective therapies for patients with GBM. Impaired DDR enables the genomic instability required for tumorigenesis, and differences in DDR functionality between tumor and normal tissue provides the fundamental rationale for using radiation therapy or genotoxic drugs as anti-cancer therapies. Additional targeted pharmacologic disruption of DDR in tumors can markedly enhance the efficacy of these cytotoxic therapies and widen the therapeutic window. In this context, we have collaborated extensively with multiple pharmaceutical companies to evaluate various small molecule DDR inhibitors and have developed significant preliminary data demonstrating profound combinatorial efficacy for these drugs when combined with radiation or alkylating chemotherapy routinely used for GBM. Thus, the initial focus for our Center is to optimize the clinical deployment of DDR inhibitors in combination with cytotoxic therapies for GBM. A Pharmacology Core will support both pharmacokinetic (PK) and pharmacodynamic (PD) evaluations in animal models and human samples, and our Therapy Evaluation Core will support both pre-clinical and clinical testing of novel therapeutic strategies. The Project and Core teams will work in close collaboration to accomplish the goals of the Center, and this collaborative effort within the Center and across the broader Glioma Therapeutics Network (GTN) will be coordinated by the Administrative Core.

项目描述/摘要——总体胶质母细胞瘤 (GBM) 有效疗法的开发一直令人难以置信，而且没有新药十多年来，任何一位 GBM 患者的治疗耐药性都可能与多种因素有关。包括广泛的肿瘤细胞浸润到邻近的大脑、肿瘤细胞群的分子异质性、为了理解和克服这些挑战，我们建立了一个过去十年中高产、多学科的科学团队，拥有跨系统的专业知识 GBM 的生物学、药理学、肿瘤生物学和动物模型在拟议的 U19 中心应用中，我们。将把这个已建立的跨学科转化科学团队与放射领域的医师科学家整合起来以及医学肿瘤学、神经外科和神经放射学，共同致力于转化新的治疗方法为 GBM 患者制定高效疗法的策略。 DDR 受损会导致肿瘤发生所需的基因组不稳定，以及 DDR 的差异肿瘤和正常组织之间的功能为使用放射治疗或基因毒性药物作为抗癌疗法可以对肿瘤中的 DDR 进行额外的靶向药理学破坏。显着增强这些细胞毒性疗法的功效并扩大治疗窗口。我们主要与多家制药公司合作评估各种小分子 DDR 抑制剂并已开发出重要的初步数据，证明了深远的组合功效因此，这些药物与常规用于 GBM 的放疗或烷化化疗相结合。我们中心的最初重点是优化 DDR 抑制剂与细胞毒性药物组合的临床部署 GBM 的治疗方法将支持药代动力学 (PK) 和药效学 (PD)。动物模型和人体样本的评估，我们的治疗评估核心将支持临床前项目和核心团队将密切合作。实现中心的目标，以及中心内部和更广泛领域的协作努力胶质瘤治疗网络 (GTN) 将由行政核心进行协调。